The objective of this article is to review the current knowledge of the pharmacology, sites of action, and therapeutic effectiveness of St. John's Wort.
Method:
The method used was a review of the available literature, using keywords to search the medline database. Bibliographies of the papers, thus obtained, were searched for further documents not referenced by medline. We reviewed papers from this collection.
Results:
This review reveals that most of the available data on efficacy and safety of St. John's Wort involve its use in mild to moderate depression. Much, but not all of the prevailing opinion is positive. Nevertheless, the quality of therapeutic trials vary so greatly that definitive conclusions are not possible. Both the source and mode of St. John's Wort's therapeutic effect are unclear. We need further controlled studies of effectiveness, safety, and mode of action. In addition to its use in depression, there are reports suggesting possible therapeutic effects in other conditions such as certain malignancies and infections, but these are far too preliminary to permit any conclusions.
AstinJA. Why patients use alternative medicine. Journal of the American Medical Association1998; 279: 1548–1553.
2.
EisenbergDMDavisRBEttnerSLAppelSWilkeySVan RompayMKesslerRC. Trends in alternative medicine use in the United States, 1990–1997. Journal of the American Medical Association1998; 280: 1569–1575.
3.
WagnerPJJesterDLeClairBTaylorATWoodwardLLambertJ. Taking the edge off: Why patients choose St. John's Wort. Journal of Family Practice1999; 48(8): 615–619.
4.
TurnerW. A new herball 1562. Cambridge: Cambridge University Press, 1995.
5.
GerardeJ. The herbal or general historie of plants gathered by John Gerarde of London, Master in Chirurgerie, very much enlarged and ammended by Thomas Johnson Citizen and Apothercarye of London. London: Adam Issip Joice Norton and Richard Witakers, 1633.
6.
CulpeperN. The English physician, or an astrologo-physical discourse on the vulgar herbs of this nation. London: Nathaniel Brook1652.
7.
Anonymous.Johanniskraut, in Herbal drugs and phytopharmaceuticals. In: BissetNG, editor. Stuttgart; Medpharm Scientific Publishers, 1994: 274–275.
8.
Anonymous.St. John's Wort, in The Lawrence review of natural products. In: OlinBR, editor. St. Louis, MO: Facts and Comparisons, 1995.
9.
BloomfieldHHNordforsMMcWilliamsP. Hypericum and depression. Los Angeles: Prelude Press, 1996.
10.
ZuessJ. The natural prozac program. New York: Three Rivers Press, 1997.
11.
NahrstedtAButterweckV. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. [Review] [74 refs]. Pharmacopsychiatry1997: 30(Suppl 2): 129–134.
12.
HoughtonPJ. St. John's Wort for depression. British Medical Journal1996; 313: 1204–1205.
13.
WagnerHBladtS. Pharmaceutical quality of Hypericum extracts. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S65–S68.
14.
CroneCCWiseYN. Use of herbal medicines among consultation-liaison populations. Psychosomatics1998; 39(1): 3–13.
15.
HarrerGSchulzV. Clinical Investigation of the antidepressant effectiveness of Hypericum. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S6–S8.
16.
ErnstE. St. John's Wort, an antidepressant? A systematic, criteria-based review. Phytomedicine1995; 2(1): 67–71.
17.
LindeKRamirezGMulrowCDPaulsAWeidenhammerWMelchartD. St. John's Wort for depression—An overview and meta-analysis of randomised clinical trials [see comments]. British Medical Journal1996; 313(7052): 253–258.
18.
VolzH-P. Controlled clinical trials of Hypericum extracts in depressed patients—An overview. Pharmacopsychiatry1997; 30(Suppl 1): S72–S76.
19.
KimHStreltzerJGoebertD. St. John's Wort for depression: A meta-analysis of well-defined clinical trials. Journal of Nervous Mental Disorders1999; 187(9): 532–538.
20.
HalamaP. Wirksamkeit des Johanniskrautextraktes LI 160 bei depressiver Verstimmung [Effectiveness of St. John's Wort extract (LI 160) in depressed dysphoria]. Nervenheilkunde1991; 10: 250–253.
21.
LehrlSWillemsenAPappRWoelkH. Ergebnisse von Messungen der kognitiven leistungsfähigkeit bei patienten unter der therapie mit Johanniskraut-Extrakt [The results of evaluation of cognitive function in patients treated with St. John's Wort extract]. Nervenheilkunde1993; 12: 281–284.
22.
SchmidtUSommerH. Johanniskraut-Extrakt zur abulanten therapie der depression [St. John's Wort extract for outpatient treatment of depression]. Fortschrift der Medizin1993; 111: 339–342.
23.
HübnerW-DLandeSPodzuweitH. Hypericum treatment of mild depressions with somatic symptoms. Journal of Geriatric Psychiatry and Neurology1994; 30: S12–S14.
24.
HarrerGHübnerW-DPodzuweitH. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotoline: A multicenter double-blind study. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S24–S28.
25.
SommerHHarrerG. Placebo-controlled double-blind study examining the effectiveness of an Hypericum preparation in 105 mildly depressed patients. Journal of Geriatric Psychiatry and Neurology1994; 7: S9–S11.
26.
VorbachE-UHübnerW-DArnoldK-H. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: Randomized double-blind study with 135 outpatients. Journal of Geriatric Psychiatry and Neurology1995: S19–S23.
27.
HänsgenKDVesperJPlochM. Multicenter double-blind study examining the antidepressant effectiveness of the Hypericum extract LI 160. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S15–S18.
28.
WheatleyD. LI 160, an extract of St. John's Wort, versus amitriptyline in mildly to moderately depressed outpatients—A controlled 6-week clinical trial. Pharmacopsychiatry1997; 30: 77–80.
29.
VorbachEUArnoldtKHHübnerW-D. Efficacy and tolerability of St. John's Wort extract LI 160 versus imipramine in patients with severe depressive episones according to ICD-10. Pharmacopsychiatry1997; 30(Suppl): 81–85.
30.
HoffmannJKühlE-D. Therapie von depressiven Zuständen mit Hypericin [Treatment of depressive states with Hypericin]. Zeitschrift für Allgemeinmedizin1979; 55: 776–782.
31.
HarrerGSchmidtUKuhnU. “Alternative” depressionsbehandlung mit einem [Alternative treatment of depression with a Hypericum extract]. Hypericum-Extract. 1991; 5: 710–716.
32.
OsterheiderMASchmidtkeHBeckmannH. Behandlung depressiver syndrome mit Hypericum (Johanniskraut) Eine placebokontrollierte Doppelbinstudie [Treatment of depressive syndromes with Hypericum (St. John's Wort) a placebo controlled double-blind study]. Forschrift fur Neurologie und Psychiatrie1992; 60(2): 210–211.
33.
QuandtJSchmidtUSchenkN. Ambulant Behandlung leichter und mittelschwerer depressiver Verstimmungen [Ambulatory treatment of mild to moderate depression]. Der Allgemeinarzt1993; 2: 97–102.
34.
LaakmannGSchuleCBaghaiTKiesserM. St. John's wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry1998; 31(Suppl 1): 54–59.
35.
EndicottJCohenJNeeJFleissJSarantakosS. Hamilton Depression Rating Scale. Archives of General Psychiatry1981; 38(1): 98–103.
36.
SchmidtUSchenkNSchwarzIVorbergG. Zur therapie depressiver verstimmungen [On the therapy of depression]. Psycho1989: 665–667.
37.
RehCLauxPSchenkN. Hypericum-Extrakt bei depressionen-eine wirksame alternative [Hypericum extract for depression—An effective alternative]. Therapiewoche1992; 42(25): 1576–1581.
38.
Anonymous. St. John's Wort. Med Lett Drugs Therapy1997; 39(1014): 107–108.
39.
HarrerGSchmidtUKuhnUBillerA. Comparison of equivalence between the St. John's Wort extract LoHyp-57 and fluoxetine. Arzneimittel-Forschung1999; 49(4): 289–296.
40.
StegerW. Depressive verstimmungen [Depression]. Zeitschrift für Allgemeinnemedizin1985.
41.
KniebelRBurchardM. Zur therapie depressiver verstimmungen in der praxis [Therapy of depression in practice]. Zeitschrift für Allgemeinmedizin1988; 64: 689–696.
42.
DitzlerKGessnerBSchattonWFHWillemsM. Clinical trial on Neuropas versus placebo in patients with mild to moderate depressive symptoms: A placebo-controlled, randomised double-blind study. Complementary Therapies in Medicine1994; 2: 5–13.
43.
DeltitoJBeyerD. The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression. Journal of Affective Diseases1998; 51(3): 345–351.
44.
WoelkHBurkardGGrünwaldJ. Benefits and risks of the Hypericum extract LI 160: Drug monitoring study with 3250 patients. Journal of Geriatric Psychiatry and Neurology1994; 30: S34–S38.
45.
KasperS. Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry1997; 30: 89–93.
46.
MartinezBKasperSRuhrmannSMöllerH-J. Hypericum in the treatment of seasonal affective disorders. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S29–S33.
47.
WarneckeG. Beeinflussung kimakterischer depressionen. Zeitschrift für Allgemeinmedizin1986; 62: 1111–1113.
48.
WerthW. Psychotonin M versus imapramin in der chirugrgie [Psychotonin M versus imipramine in surgery]. Der Kassenartz1989; 15: 64–68.
49.
SchulzHJobertM. Effects of Hypericum extract on the sleep EEG in older volunteers. Journal of Geriatric Psychiatry and Neurology1994; 30: S39–S43.
50.
BrockmöllerJReumTBauerSKerbRHübnerWDRootsI. Hypericin and pseudohypericin: Pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry1997; 30(Suppl 2): 94–101.
51.
BerndASimonSBoscaRamirez AKippenbergerSAlperiDiaz JMiguelJGarciaVillalba JFMiraPamies DKaufmannR. Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. Photochemistry and Photobiology1999; 69(2): 218–221.
52.
GolschSVocksERakoskiJBrockowKRingJ. [Reversible increase in photosensitivity to UV-B caused by St. John's Wort extract]. Hautarzt1997; 48(4): 249–252.
53.
JamesJS. Hypericin. AIDS Treatment News1992; 146: 1–4.
54.
CzekallaJGastparMHubnerWDJagerD. The effect of Hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry1997; 30(Suppl 2): 86–88.
55.
OndrizekRRChanPJPattonWCKingA. Inhibition of human sperm motility by specific herbs used in alternative medicine [In Process Citation]. Journal of Assisted Reproduction and Genetics1999; 16(2): 87–91.
56.
OndrizekRRChanPJPattonWCKingA. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertility and Sterility1999; 71(3): 517–522.
57.
OkpanyiSNLidzbaHSchollBCMiltenburgerHG. Genotoxizitat eines standardisierten Hypericum-Extraktes [Genetic toxicity of a standardized extract of Hypericum]. Arzneimittelforschung1990; 40(8): 851–855.
58.
JohneABrockmollerJBauerSMaurerALangheinrichMRootsI. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's Wort. Clinical Pharmacology and Therapeutics1999; 66(4): 338–345.
59.
ErnstE. Second thoughts about safety of St. John's Wort. Lancet1999; 354: 2014–2016.
60.
DeMottK. St. John's Wort tied to serotonin syndrome. Clinical Psychiatry News, 1998: 28.
61.
GordonJB. SSRI's and St. John's Wort: Possible toxicity [letter]. American Family Physician1998; 57: 952–953.
62.
SchneckC. St. John's Wort and Hypomania [letter]. Journal of Clinical Psychiatry1998; 59: 12.
63.
KhawajaISMarottaRFLippmannS. Herbal medicines as a factor in delirium. Psychiatric Services1999; 50(7): 969–970.
64.
ThiedeHMWalperA. Inhibition of MAO and COMT by Hypericum extracts and hypericin. Journal of Geriatric Psychiatry and Neurolog1994; 7(Suppl 1): S54–S56.
65.
CottJM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry1997; 30(Suppl 2): 108–112.
66.
MüllerWESchäferC. Johanniskraut: In-vitro studie über Hypericum-extract, hypericin und Kampferol [An in vitro study of hypericum extract, hypericin and kampferol]. Deutsche Apotheker Zxeitung1996; 136: 1015–1022.
67.
RolliMSchaferCMullerWE. Effect of Hypericum extract (LI 160) on neurotransmitter receptor binding and synaptosomal uptake systems. Pharmacopsychiatry1995; 28: 207.
68.
PerovicSMüllerWEG. Pharamacological profile of Hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung1995; 45(11): 1145–1148.
69.
MüllerWESingerAWonnemannMHafnerURolliMSchäferC. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry1998; 31(Suppl 1): 16–21.
70.
NearyJTBuY. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Research1999; 816(2): 358–363.
71.
NathanP. The experimental and clinical pharmacology of St. John's Wort (Hypericum perforatum L.). Molecular Psychiatry1999; 4(4): 333–338.
72.
FranklinMChiJMcGavinCHockneyRReedACamplingGWhaleRWRCowenR. Neuroendocrine evidence for dopaminergic actions of Hypericum extract (LI 160) in healthy volunteers. Biological Psychiatry1999; 46: 581–584.
73.
ThieleBBrinkIPlochM. Modulation of cytokine expression by Hypericum extract. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S60–S62.
74.
MüllerWEGRossolR. Effects of Hypericum extract on the expression of serotonin receptors. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S63–S64.
75.
Teufel-MayerRGleitzJ. Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry1997; 30(Suppl 2): 113–116.
76.
BennettDAJr.PhunLPolkJFVoglinoSAZlotnikVRaffaRB. Neuropharmacology of St. John's Wort (Hypericum). Annals of Pharmacotherapy1998; 32(11): 1201–1208.
77.
SuzukiOKatsumaYOyaMBladtSWagnerH. Inhibition of monoamine oxidase by hypericin. Planta Medicin1984; 50: 272–274.
78.
BlumenthalMBusseWRGoldbergAGruenwaldJHallTRigginsCWRisterRS, (eds). The complete German commission E monographs: Therapeutic guide to herbal medicines. Boston, MA: American Botanical Council, 1998.
79.
BladtSWagnerH. Inhibition of MAO by fractions and constituents of Hypericum extract. Journal of Geriatric Psychiatry and Neurology1994; 7(Suppl 1): S57–S59.
80.
UptonRBuntingDButterweckVCottJCatherumDMGraffA. St. John's Wort (Hypericum perforatum), in St. John's Wort. Santa Cruz, CA: American Herbal Pharmacopoeia, 1997.
81.
BaureithelKHBüterKBEngesserABurkardWSchaffnerW. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharmaceutica Acta Helvetiae1997; 72(3): 153–157.
82.
NielsonMFrokaerSBaestrupC. High affinity of the naturally occurring bioflavonoid, amentoflavone, to brain benzodiazepine receptors in vitro. Bichemical Pharmacology1988; 37: 3285–3287.
83.
BhattacharyaSKChakrabartiAChatterjeeSS. Activity profiles of two hyperforin-containing Hypericum extracts in behavioral modelsPharmacopsychiatry1998; 31(Suppl 1): 22–29.
84.
ChatterjeeSSNöldnerMKochEErdelmeierC. Antidepressant activity of Hypericum perforatum and hyperforin: The neglected possibility. Pharmacopsychiatry1998; 31(Suppl 1): 7–15.
85.
DiwuZ. Novel therapeutic and diagnostic applications of hypocrellins and hypercins. Photochem Photobiology1995; 61(6): 529–539.
86.
SchemppCMPetzKWittmerASchopfESimonJC. Antibacterial activity of hyperforin from St. John's Wort, against multiresistant Staphylococcus aureus and gram positive bacteria. Lancet1999; 353: 2129.
87.
ChuntP-SSaxtonREPaivaMBRheeC-KSoudantJMatheyAFooteCCastroDJ. Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: Study of a new sensitizer for laser phototherapy. Laryngoscope1994; 104: 1471–1477.
88.
CouldwellWTGopalakrishnaRHintonDRHeSWeissMHLawREApuzzoMLJ. Hypericin: A potential antiglioma therapy. Neurosurgery1994; 35: 705–709.
89.
Fugh-BermanACottJM. Dietary supplements and natural products as psychotherapeutic agents. Psychosomatic Medicine1999; 61: 712–728.
90.
BenderKJ. St. John's Wort in NIH antidepressant trial, in Psychiatric Times. Irvine, CA: 1998.
91.
BergmannRNüssnerJDemlingJ. Behandlung leichter bis mittelschwerer depressionen vergleich von Hypericum perforatum mit amitriptylin [Treatment of mild to moderate depression comparing hypericum perforatum to amitripyline. TW Neurologie Psychiatrie1993; 7(April 1993):235–240.
92.
RaffaRB. Screen of receptor and uptake-site activity of hypericin component of St. John's Wort reveals sigma receptor binding. Life Sciences1998; 62(16): L265–L270.
93.
KaehlerSTSinnerCChatterjeeSSPhilippuA. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus [In Process Citation]. Neuroscience Letters1999; 262(3): 199–202.
